发明名称 ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
摘要 The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
申请公布号 US2015337042(A1) 申请公布日期 2015.11.26
申请号 US201514664453 申请日期 2015.03.20
申请人 ABBVIE INC. 发明人 Reilly Edward B.;Phillips Andrew C.;Benatuil Lorenzo;Buchanan Fritz G.;Meulbroek Jonathan A.;Hsieh Chung-Ming;Perez Jennifer
分类号 C07K16/28;A61K47/48 主分类号 C07K16/28
代理机构 代理人
主权项 1. An anti-human epidermal growth factor receptor (anti-hEGFR) antibody, or antigen binding portion thereof, that a) binds to an epitope within the amino acid sequence CGADSYEMEEDGVRKC (SEQ ID NO: 45) or competes with a second anti-hEGFR antibody for binding to epidermal growth factor receptor variant III (EGFRvIII) (SEQ ID NO: 33) in a competitive binding assay, wherein the second anti-EGFR antibody comprises a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 5; b) binds to EGFR(1-525) (SEQ ID NO: 47) with a dissociation constant (Kd) of about 1×10−6 M or less, as determined by surface plasmon resonance; and c) inhibits tumor growth in an in vivo human non-small-cell lung carcinoma (NSCLC) xenograft assay with a tumor growth inhibition % (TGI %) of at least about 50% relative to a human IgG antibody which is not specific for EGFR, wherein the human IgG antibody is administered in the NSCLC xenograft assay at the same dose and frequency as the anti-hEGFR antibody, or antigen binding portion thereof.
地址 North Chicago IL US